GLUCOCORTICOIDS IN CHRONIC DISEASE: THE GOOD, THE BAD, THE BONE

Overview

Journal Trans Am Clin Climatol Assoc

Specialty Rehabilitation Medicine

Date 2023 Sep 13

PMID 37701582

Authors

Kenneth G Saag

Affiliations

Soon will be listed here.

Abstract

Despite the advent of more targeted therapies, glucocorticoids (steroids) remain in chronic use (defined as > 3 months or more) by an estimated 0.5% of the population. Steroids yield symptomatic benefits for systemic and local inflammation as well as disease-modifying properties in rheumatoid arthritis, the most common disorder for their chronic use. Despite their many benefits, steroids have been associated with a myriad of common side effects. Observational studies of steroid safety are limited by confounding by indication, and randomized controlled trials have been too short and too small to understand their true safety profile. Glucocorticoid-induced osteoporosis (GIOP) occurs in a time- and dose-dependent way and is associated with both a reduction in bone formation and an increase in bone resorption. Numerous anti-osteoporotic therapies have efficacy for improving bone health among chronic glucocorticoid users, but implementation science approaches are needed to achieve adequate GIOP prevention and to reduce fracture outcomes.

Citing Articles

Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis.

Grygorieva N, Kovalenko V, korzh M, Tronko M, Golovach I, Dedukh N Arch Osteoporos. 2025; 20(1):31.

PMID: 39992470 DOI: 10.1007/s11657-025-01512-9.

References

van Staa T, Leufkens H, Abenhaim L, Zhang B, Cooper C . Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2001; 39(12):1383-9. DOI: 10.1093/rheumatology/39.12.1383. View

Walsh L, Wong C, Pringle M, Tattersfield A . Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996; 313(7053):344-6. PMC: 2351752. DOI: 10.1136/bmj.313.7053.344. View

Saag K, Shane E, Boonen S, Marin F, Donley D, Taylor K . Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357(20):2028-39. DOI: 10.1056/NEJMoa071408. View

Reid D, Devogelaer J, Saag K, Roux C, Lau C, Reginster J . Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373(9671):1253-63. DOI: 10.1016/S0140-6736(09)60250-6. View

Pincus T, Sokka T, Stein C . Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?. Ann Intern Med. 2002; 136(1):76-8. DOI: 10.7326/0003-4819-136-1-200201010-00013. View

Kirwan J . The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995; 333(3):142-6. DOI: 10.1056/NEJM199507203330302. View

Saag K, Koehnke R, Caldwell J, Brasington R, Burmeister L, Zimmerman B . Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994; 96(2):115-23. DOI: 10.1016/0002-9343(94)90131-7. View

Saag K, Criswell L, Sems K, Nettleman M, Kolluri S . Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum. 1996; 39(11):1818-25. DOI: 10.1002/art.1780391107. View

De Bosscher K, Van Craenenbroeck K, Meijer O, Haegeman G . Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems. Eur J Pharmacol. 2008; 583(2-3):290-302. DOI: 10.1016/j.ejphar.2007.11.076. View

10.

Laan R, van Riel P, van de Putte L, van Erning L, vant Hof M, Lemmens J . Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993; 119(10):963-8. DOI: 10.7326/0003-4819-119-10-199311150-00001. View

11.

Van Everdingen A, Jacobs J, Siewertsz van Reesema D, Bijlsma J . Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002; 136(1):1-12. DOI: 10.7326/0003-4819-136-1-200201010-00006. View

12.

Grijalva C, Chung C, Stein C, Mitchel Jr E, Griffin M . Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. Rheumatology (Oxford). 2008; 47(7):1061-4. PMC: 4819998. DOI: 10.1093/rheumatology/ken193. View

13.

Cohen S, Levy R, Keller M, BOLING E, Emkey R, Greenwald M . Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999; 42(11):2309-18. DOI: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K. View

14.

Amiche M, Albaum J, Tadrous M, Pechlivanoglou P, Levesque L, Adachi J . Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2015; 27(5):1709-18. DOI: 10.1007/s00198-015-3455-9. View

15.

Stoch S, Saag K, Greenwald M, Sebba A, Cohen S, Verbruggen N . Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 2009; 36(8):1705-14. DOI: 10.3899/jrheum.081207. View

16.

Adachi J, Saag K, Delmas P, Liberman U, Emkey R, Seeman E . Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44(1):202-11. DOI: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W. View

17.

Saag K, Zanchetta J, Devogelaer J, Adler R, Eastell R, See K . Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60(11):3346-55. DOI: 10.1002/art.24879. View

18.

Emkey R, Lindsay R, Lyssy J, Weisberg J, Dempster D, Shen V . The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum. 1996; 39(2):277-82. DOI: 10.1002/art.1780390215. View

19.

Criswell L, Redfearn W . Variation among rheumatologists in the use of prednisone and second-line agents for the treatment of rheumatoid arthritis. Arthritis Rheum. 1994; 37(4):476-80. DOI: 10.1002/art.1780370407. View

20.

Hench P, KENDALL E, Slocumb C, POLLEY H . Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic). 1950; 85(4):545-666. DOI: 10.1001/archinte.1950.00230100002001. View